Skip to content

Quarter 3

Pulse on Progress

Table of Contents

Introduction

TransCelerate aspires for a future state where research and development is faster, more efficient and harnesses all the available information. We envision this happening in three ways:
  1. Full participation across all stakeholders – clinical trial sponsors, sites, investigators, health authorities, patients, and their healthcare providers
  2. Information is fully used to improve the overall quality, design, and development process. We protect patients through shared, proactive safety science
  3. Improving the execution of research and development through greater harmonization with the potential to conduct collaborative trials

Newest Resources and Company Milestones

  • TransCelerate announced that COO Janice Chang has been appointed as TransCelerate’s new Chief Executive Officer. Janice will assume the role on January 1, 2023. Janice, who joined TransCelerate in 2014, will succeed founding CEO Dalvir Gill, Ph.D., who announced his retirement after a long and successful career in drug development spanning over 30 years.
  • In celebration of TransCelerate’s 10-Year Anniversary, our Board Members have been sharing their insights and thoughts about the successes and progress that TransCelerate has made over the last decade. You can watch these videos on our YouTube page to learn more about the overall impact TransCelerate has made within the R&D ecosystem. Q3’s experts include former Board of Directors contributor Peter Ronco, Head of Global Development, Janssen Research & Development.

Pulse On Progress Updates

Information Sharing & Harmonization
Objectives

Enable the industry to move toward greater harmonization of process and facilitate the sharing of information amongst industry stakeholders to enable the industry to capture, optimize and experience efficiencies.


Improve the Patient & Site Experience
Objectives

Improve the patient and site experience by decreasing burden, enabling a better-informed patient and improving clinical research awareness, participation & engagement.


Enhance Drug Safety
Objectives

Facilitate solutions that address a common set of challenges in drug safety surveillance such as engaging the public, collaborating with regulators, incorporating data and analytics, developing model approaches, and assessing the impact of efforts.


Check Out Our Blog

And if you haven’t already, check out our recent blog posts and media placements to learn about what we’ve been up to this past quarter:


Have Questions?

Please direct all inquiries as specified below:


Keep Up with Us!


Mark Your Calendars

TransCelerate leaders and Member Companies are invited to participate and present at many biopharmaceutical research industry conferences and meetings across the globe to provide a perspective on industry challenges and clinical trial issues. Take a peek at a few places we will be presenting in the coming months. For detailed information on speaker presentations, visit the events page on the TransCelerate website.

October 26-27, 2022

2022 CDISC U.S. Interchange

Austin, TX

November 1

TransCelerate Webinar: Digital Data Flow-Connectathon Results & Outcomes

Virtual

November 7-9

Clinical Trials Europe

Amsterdam, Netherlands

November 13-16

American College of Toxicology Annual Meeting

Denver, CO


X